Sorted By Test Name - Mayo Medical Laboratories

ANAH2
86038
Interpretation: Positive results for proteinase 3 (PR3) antineutrophil cytoplasmic antibodies (ANCA)
and cANCA or pANCA are consistent with the diagnosis of Wegener's granulomatosis (WG), either
systemic WG with respiratory and renal involvement or limited WG with more restricted end-organ
involvement. Positive results for MPO ANCA and pANCA are consistent with the diagnosis of
autoimmune vasculitis including microscopic polyangiitis (MPA) or pauci-immune necrotizing
glomerulonephritis. A positive result for PR3 ANCA or MPO ANCA has been shown to detect 89% of
patients with active WG or MPA (with or without renal involvement) with fewer than 1% false-positive
results in patients with other diseases.(1)
Reference Values:
MYELOPEROXIDASE ANTIBODIES, IgG
or =1.0 U (positive)
Reference values apply to all ages.
PROTEINASE 3 ANTIBODIES, IgG
or =1.0 U (positive)
Reference values apply to all ages.
Clinical References: 1. Russell KA, Wiegert E, Schroeder DR, et al: Detection of anti-neutrophil
cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002 May;103(2):196-203
2. Specks U, Homburger HA, DeRemee RA: Implications of cANCA testing for the classifications of
Wegner's Granulomatosis: performance of different detection systems. Adv Exp Med Biol
1993;336:65-70
Antinuclear Antibodies (ANA), HEp-2 Substrate, Serum
Clinical Information: Antinuclear antibodies are seen in a number of autoimmune disorders such as
systemic lupus erythematosus; mixed connective tissue disease; rheumatoid arthritis; Sjogren syndrome;
progressive systemic sclerosis; and calcinosis, Raynaud phenomenon, esophageal dysmotility, syndactyly,
and telangiectasia (CREST) syndrome.
Useful For: Diagnosis of autoimmune diseases
Interpretation: Anticentromere antibody (ACA) pattern: -A positive test for ACA is strongly
associated with calcinosis, Raynaud phenomenon, esophageal dysmotility, syndactyly, and telangiectasia
(CREST) syndrome; in various reported clinical studies ACA occurs in 50% to 96% of patients with
CREST syndrome. -The presence of detectable levels of ACA may antedate the appearance of diagnostic
clinical features of CREST syndrome, in some cases by several years. The incidence of low-titer
antinuclear antibodies (ANA) positives increases with age in normal individuals. For positive ANA titers
of > or =1:160, and for all ANA titers whenever there is a strong clinical suspicion of rheumatic disease,
we recommend follow up using the assays ADNA/200043 DNA Double-Stranded (dsDNA) Antibodies,
IgG, Serum and ENAE/200047 Antibody to Extractable Nuclear Antigen Evaluation, Serum.
Reference Values:
Negative (titer of